The safety of vedolizumab for ulcerative colitis and Crohn's disease
Jean‐Frédéric Colombel(Mount Sinai Hospital), Brian G. Feagan(Western University), Remo Panaccione(University of Calgary), Bruce E. Sands(Icahn School of Medicine at Mount Sinai), William J. Sandborn(University of San Diego), Silvio Danese(IRCCS Ospedale San Raffaele), Edward V. Loftus(Mayo Clinic), Geert D’Haens(Amsterdam University Medical Centers), Serap Sankoh(Millennium Engineering and Integration (United States)), Paul Rutgeerts(KU Leuven), Asit Parikh, Catherine Milch(Millennium Engineering and Integration (United States)), Brihad Abhyankar(Takeda (United Kingdom)), Irving H. Fox(Takeda (United States))
Cited by 810
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k